Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 5/20 | 0.47 |
| ▸ | ESRRA | P11474 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 4/20 | 0.42 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CASP6 | P55212 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14656239 | 0.87 | SLC22A12 (0.47) | SLC22A12ESRRAARTRPV4ALDH1A1 | |
| SCHEMBL14661910 | 0.85 | AR (0.50) | SLC22A12ESRRAARTRPV4 | |
| SCHEMBL25285812 | 0.85 | CYP19A1 (0.50) | ESRRAARPARP10PARP3ALDH1A1 | |
| SCHEMBL29965252 | 0.85 | CYP19A1 (0.50) | ESRRAARPARP10PARP3ALDH1A1 | |
| SCHEMBL10535321 | 0.85 | TRPV4 (0.55) | SLC22A12ARTRPV4CYP11B1CYP11B2 | |
| SCHEMBL8551880 | 0.83 | AR (0.53) | ESRRAARPARP10PARP3POLB | |
| SCHEMBL923510 | 0.81 | TRPV4 (0.52) | TRPV4ALDH1A1SMN1; SMN2CYP11B1CYP11B2 | |
| SCHEMBL29630883 | 0.81 | TRPV4 (0.52) | TRPV4ALDH1A1SMN1; SMN2CYP11B1CYP11B2 | |
| SCHEMBL3696845 | 0.81 | AR (0.51) | SLC22A12ESRRAARTRPV4PARP10 | |
| SCHEMBL14662287 | 0.80 | AR (0.54) | ESRRAAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1699783-B1 | OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2012-07-25 | — | — | EP | disclosed |
| EP-1699783-B1 | OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2012-07-25 | — | — | EP | disclosed |
| US-7414132-B2 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-08-19 | — | — | US | disclosed |
| US-7414132-B2 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-08-19 | — | — | US | disclosed |
| US-7414132-B2 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-08-19 | — | — | US | disclosed |
| US-20070112036-A1 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-05-17 | — | — | US | disclosed |
| US-20070112036-A1 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-05-17 | — | — | US | disclosed |
| US-20070112036-A1 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-05-17 | — | — | US | disclosed |
| EP-1699783-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005066164-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112036-A1 | Opioid receptor antagonists | OPRM1, OPRD1, OPRK1 | SLC22A12 1892/4885ESRRA 88/4885AR 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.